| Literature DB >> 32302308 |
Laura K Murray1, Jeremy C Kane1,2, Nancy Glass3, Stephanie Skavenski van Wyk1, Flor Melendez1, Ravi Paul4, Carla Kmett Danielson5, Sarah M Murray1, John Mayeya6, Francis Simenda7, Paul Bolton8.
Abstract
BACKGROUND: Both intimate partner violence (IPV) and alcohol misuse are highly prevalent, and partner alcohol misuse is a significant contributor to women's risk for IPV. There are few evidence-based interventions to address these problems in low- and middle-income countries (LMICs). We evaluated the effectiveness of an evidence-based, multi-problem, flexible, transdiagnostic intervention, the Common Elements Treatment Approach (CETA) in reducing (a) women's experience of IPV and (b) their male partner's alcohol misuse among couples in urban Zambia. METHODS ANDEntities:
Year: 2020 PMID: 32302308 PMCID: PMC7164585 DOI: 10.1371/journal.pmed.1003056
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Fig 1Trial flow diagram.
CETA, Common Elements Treatment Approach; TAU-Plus, treatment as usual plus safety checks.
Baseline characteristics of study sample.
| CETA ( | TAU-Plus ( | |
|---|---|---|
| 18–25 | 28 (23%) | 37 (30%) |
| 26–35 | 56 (46%) | 43 (34%) |
| 36–45 | 24 (19%) | 25 (20%) |
| 46–55 | 11 (9%) | 14 (11%) |
| 56–65 | 4 (3%) | 3 (2%) |
| 66+ | 0 (0%) | 2 (2%) |
| Missing | 0 (0%) | 1 (1%) |
| 18–25 | 18 (15%) | 9 (7%) |
| 26–35 | 41 (33%) | 53 (43%) |
| 36–45 | 39 (32%) | 35 (28%) |
| 46–55 | 18 (15%) | 19 (15%) |
| 56–65 | 5 (4%) | 6 (5%) |
| 66+ | 2 (1%) | 3 (2%) |
| None | 30 (24%) | 28 (22%) |
| Some primary | 53 (43%) | 53 (42%) |
| Completed primary | 21 (17%) | 25 (20%) |
| Completed secondary | 7 (6%) | 12 (10%) |
| Completed higher than secondary | 2 (2%) | 2 (2%) |
| Other | 10 (8%) | 5 (4%) |
| None | 19 (15%) | 11 (9%) |
| Some primary | 40 (33%) | 51 (41%) |
| Completed primary | 26 (21%) | 24 (19%) |
| Completed secondary | 28 (23%) | 31 (25%) |
| Completed higher than secondary | 4 (3%) | 5 (4%) |
| Other | 6 (5%) | 3 (2%) |
| Formally employed | 9 (7%) | 3 (2%) |
| Informally employed | 23 (19%) | 19 (15%) |
| Part-time employed | 20 (16%) | 28 (23%) |
| Unemployed and looking for work | 59 (48%) | 66 (53%) |
| Unemployed and not looking for work | 12 (10%) | 9 (7%) |
| Formally employed | 14 (11%) | 8 (7%) |
| Informally employed | 36 (29%) | 28 (22%) |
| Part-time employed | 28 (23%) | 23 (18%) |
| Unemployed and looking for work | 42 (34%) | 59 (47%) |
| Unemployed and not looking for work | 3 (3%) | 7 (6%) |
| Spouse | 47 (38%) | 45 (36%) |
| Dating but not living together | 9 (7%) | 7 (6%) |
| Dating and living together | 48 (39%) | 61 (49%) |
| Other | 19 (16%) | 12 (9%) |
| 83 (68%) | 84 (67%) | |
| 74 (61%) | 66 (53%) | |
| 55 (45%) | 46 (37%) | |
| 36 (30%) | 30 (24%) | |
| 7.7 (5.5) | 6.7 (4.6) | |
| 6.6 (5.3) | 6.0 (5.0) | |
| 168.7 (75.8) | 187.9 (44.3) | |
| 168.4 (59.0) | 192.8 (49.4) | |
| 389.9 (27.9) | 383.9 (24.4) | |
| 391.2 (32.3) | 384.3 (30.3) |
Data are n (%) or mean (SD).
CETA, Common Elements Treatment Approach; TAU-Plus, treatment as usual plus safety checks.
Intervention effect of CETA on violence outcomes.
| Outcome | CETA ( | TAU-Plus ( | Between-group treatment effect | |||
|---|---|---|---|---|---|---|
| Mean or | Mean change from baseline or relative risk | Mean or | Mean change from baseline or relative risk | Difference in mean change | Cohen’s | |
| Baseline | 65.2 | — | 61.8 | — | — | — |
| (62.0 to 68.3) | (60.4 to 63.2) | |||||
| End of treatment | 38.6 | −26.5 | 46.6 | −15.2 | −11.3 | 0.67 |
| (34.5 to 42.8) | (−30.5 to −22.5) | (42.7 to 50.5) | (−18.8 to −11.6) | (−16.7 to −5.8) | ||
| 12-month | 41.9 | −23.2 | 46.8 | −15.0 | −8.2 | 0.49 |
| (37.6 to 46.2) | (−27.1 to −19.4) | (41.1 to 52.4) | (−20.6 to −9.5) | (−14.9 to −1.5) | ||
| Baseline | 46.7 | — | 46.1 | — | — | — |
| (43.8 to 49.6) | (44.9 to 47.1) | |||||
| End of treatment | 27.9 | −18.8 | 33.5 | −12.6 | −6.2 | 0.49 |
| (24.6 to 31.2) | (−21.5 to −16.1) | (32.2 to 34.7) | (−13.6 to −11.5) | (−9.2 to −3.3) | ||
| 12-month | 29.7 | −17.0 | 33.2 | −12.9 | −4.2 | 0.33 |
| (26.2 to 31.1) | (−20.1 to −14.0) | (30.9 to 35.4) | (−15.4 to −10.4) | (−8.0 to −0.3) | ||
| Baseline | 98 (80%) | — | 96 (77%) | — | — | |
| (90 to 108) | (90 to 104) | |||||
| End of treatment | 43 (35%) | 0.43 | 63 (50%) | 0.65 | 0.66 | |
| (33 to 55) | (0.34 to 0.56) | (56 to 69) | (0.61 to 0.70) | (0.51 to 0.87) | ||
| 12-month | 47 (38%) | 0.47 | 60 (48%) | 0.63 | 0.75 | |
| (42 to 77) | (0.37 to 0.61) | (51 to 70) | (0.56 to 0.69) | (0.57 to 0.99) | ||
| Baseline | 98 (80%) | — | 94 (75%) | —− | — | |
| (93 to 105) | (86 to 103) | |||||
| End of treatment | 31 (25%) | 0.31 | 68 (54%) | 0.73 | 0.43 | |
| (21 to 47) | (0.22 to 0.45) | (64 to 71) | (0.67 to 0.79) | (0.30 to 0.63) | ||
| 12-month | 47 (38%) | 0.48 | 61 (49%) | 0.66 | 0.73 | |
| (37 to 58) | (0.38 to 0.59) | (51 to 73) | (0.54 to 0.79) | (0.54 to 0.98) | ||
| Baseline | 101 (82%) | — | 88 (70%) | — | — | |
| (89 to 113) | (80 to 95) | |||||
| End of treatment | 43 (35%) | 0.43 | 65 (52%) | 0.74 | 0.58 | |
| (34 to 55) | (0.35 to 0.54) | (56 to 69) | (0.68 to 0.80) | (0.46 to 0.74) | ||
| 12-month | 44 (36%) | 0.44 | 59 (47%) | 0.68 | 0.65 | |
| (32 to 60) | (0.35 to 0.55) | (51 to 69) | (0.55 to 0.83) | (0.48 to 0.88) | ||
| Baseline | 64 (52%) | — | 54 (43%) | — | — | |
| (55 to 75) | (48 to 60) | |||||
| End of treatment | 27 (22%) | 0.42 | 53 (42%) | 0.99 | 0.42 | |
| (18 to 38) | (0.30 to 0.59) | (48 to 59) | (0.89 to 1.1) | (0.30 to 0.60) | ||
| 0.86 | ||||||
| 12-month | 37 (30%) | 0.58 | 45 (36%) | 0.84 | 0.68 | |
| (27 to 52) | (0.40 to 0.82) | (36 to 56) | (0.70 to 0.99) | (0.46 to 1.0) | ||
| 0.06 | ||||||
α = Cronbach’s alpha for internal reliability. Estimates for mean, SD, mean change from baseline, difference in mean change, risk percent, RR, and ratio of relative risk are based on predicted values from mixed effects models. For binary outcomes, Ns are calculated based on predicted percent. All participants were included in the analysis following multiple imputation of missing data. Cohen’s d effect size was calculated by dividing the predicted difference in mean change from the mixed effects model by the pooled baseline SD. Within-group RRs represent the change in risk from baseline to each post-baseline assessment. RRs < 1 indicate a reduction in risk. The ratio of RRs is the exponentiated group by time interaction term and represents the ratio of the CETA RR to the TAU-Plus RR. Between-group ratio of RRs < 1 indicates a greater reduction in risk from baseline to follow-up in the CETA group compared to the TAU-Plus group. All models included fixed effects of treatment arm, time, and the interaction term of treatment × time as well as random effects of participant ID and counselor ID. Additional fixed effect demographic variables were included as covariates if they differed meaningfully at baseline between the treatment groups or if the variable predicted change in the outcome over time. Specific variables included in each model are listed in S1 Table. Baseline and 12-month post-baseline assessments had an IPV reference period of the past 12 months; the post-treatment assessment had a reference period of the past 3 months. Bold indicates significant p-value.
CETA, Common Elements Treatment Approach; F, female report of experiencing recent violence; IPV, intimate partner violence; M, male report of perpetrating recent violence; RR, relative risk; SVAWS, Severity of Violence Against Women Scale; TAU-Plus, treatment as usual plus safety checks.
Fig 2Change in female reporting of recent physical and sexual violence among those receiving CETA and TAU-Plus.
The difference in change from baseline to post-treatment and from baseline to 12 months post-baseline between the groups was statistically significant for both physical and sexual violence (p < 0.05). Baseline and 12-month post-baseline assessments had an intimate partner violence reference period of the past 12 months; the post-treatment assessment had a reference period of the past 3 months. CETA, Common Elements Treatment Approach; TAU-Plus, treatment as usual plus safety checks.
Intervention effect of CETA on alcohol outcomes.
| AUDIT score | CETA ( | TAU-Plus ( | Between-group treatment effect | |||
|---|---|---|---|---|---|---|
| Mean | Mean change from baseline | Mean | Mean change from baseline | Difference in mean change | Cohen’s | |
| (95% CI) | ||||||
| Baseline | 14.9 | — | 14.6 | — | — | — |
| (13.3 to 16.4) | (13.8 to 15.4) | |||||
| End of treatment | 5.7 | −9.2 | 10.0 | −4.5 | −4.7 | 0.45 |
| (4.1 to 7.3) | (−11.7 to −6.6) | (8.8 to 11.3) | (−5.7 to −3.4) | (−7.5 to −1.8) | ||
| 12-month | 5.7 | −9.2 | 9.9 | −4.7 | −4.5 | 0.43 |
| (3.7 to 7.7) | (−11.3 to −7.1) | (8.7 to 11.1) | (−6.9 to −2.2) | (−6.9 to −2.2) | ||
| Baseline | 21.7 | — | 19.5 | — | — | — |
| (19.9 to 23.6) | (18.9 to 20.1) | |||||
| End of treatment | 9.1 | −12.7 | 12.1 | −7.4 | −5.3 | 0.56 |
| (6.9 to 11.2) | (−15.2 to −10.1) | (10.7 to 13.5) | (−8.5 to −6.3) | (−8.0 to −2.5) | ||
| 12-month | 10.0 | −11.8 | 13.4 | −6.1 | −5.6 | 0.59 |
| (7.9 to 12.0) | (−14.3 to −9.3) | (11.7 to 15.1) | (−7.4 to −4.8) | (−8.5 to −2.8) | ||
| Baseline | 11.8 | — | 9.6 | — | — | — |
| (9.9 to 13.6) | (6.9 to 12.4) | |||||
| End of treatment | 4.5 | −7.2 | 5.3 | −4.3 | −2.9 | 0.26 |
| (2.6 to 6.4) | (−9.7 to −4.8) | (2.6 to 8.0) | (−5.4 to −3.2) | (−5.6 to −0.2) | ||
| 12-month | 5.7 | −6.0 | 6.7 | −2.9 | −3.1 | 0.28 |
| (3.7 to 7.8) | (−7.6 to −4.5) | (5.2 to 8.3) | (−4.4 to −1.4) | (−5.3 to −0.99) | ||
| Baseline | 9.9 | — | 9.0 | — | — | — |
| (8.2 to 11.6) | (7.4 to 10.6) | |||||
| End of treatment | 5.7 | −4.2 | 7.0 | −2.0 | −2.2 | 0.24 |
| (4.0 to 7.4) | (−6.5 to −1.9) | (5.7 to 8.4) | (−3.0 to −0.9) | (−4.7 to 0.3) | ||
| 0.08 | ||||||
| 12-month | 6.2 | −3.6 | 7.2 | −1.8 | −1.9 | 0.21 |
| (4.5 to 8.0) | (−5.1 to −2.2) | (5.9 to 8.5) | (−3.1 to −0.5) | (−3.9 to 0.1) | ||
| 0.07 | ||||||
α = Cronbach’s alpha for internal reliability. Estimates for mean, SD, mean change from baseline, and difference in mean change are based on predicted values from mixed effects models. Cohen’s d effect size was calculated by dividing the predicted difference in mean change from the mixed effects model by the pooled baseline SD. All models included fixed effects of treatment arm, time, and the interaction term of treatment × time, as well as random effects of participant ID and counselor ID. Additional fixed effect demographic variables were included as covariates if they differed meaningfully at baseline between the treatment groups or if the variable predicted change in the outcome over time. Specific variables included in each model are listed in S1 Table. Bold indicates significant p-value.
AUDIT, Alcohol Use Disorders Identification Test; CETA, Common Elements Treatment Approach; TAU-Plus, treatment as usual plus safety checks.
Fig 3Change in male drinking among those receiving CETA and TAU-Plus as self-reported by the male and partner-reported by the female on AUDIT.
The difference in change from baseline to post-treatment and from baseline to 12 months post-baseline between the groups was statistically significant for both male self-report and female partner-report (p < 0.05). AUDIT, Alcohol Use Disorders Identification Test; CETA, Common Elements Treatment Approach; TAU-Plus, treatment as usual plus safety checks.